Laekna’s LAE002(Afuresertib) + LAE001 Receives FDA Approval for P-III Trial Protocol to Treat Prostate Cancer
Shots:
- Laekna’s combination therapy LAE201 (LAE002 + LAE001), has received US FDA approval for P-III trial protocol to treat mCRPC following SoC treatment
- P-III trial design has been discussed with FDA based on P-II study data, shown reassuring anti-tumor activity and safety profile with mrPFS of 8.1mos. to treat mCRPC patients (n=40) progressed on 1–3L of standard treatments (at least 1L of abiraterone or 2L AR antagonists)
- LAE002 (afuresertib), is an AKT inhibitor and LAE001, is CYP17A1/CYP11B2 dual inhibitor
Ref: Laekna | Image: Laekna
Related News:- Laekna Acquires Exclusive WW Rights of Two Oncology Clinical Stage Candidates from Novartis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies, FDA, EMA, and biosimilar approvals. He can be contacted at connect@pharmashots.com
